NGNE Neurogene Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1404644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-40.0%
TTM EPS YoY-22.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.4%
ROA-35.8%
ROIC (approx.)-43.7%
Asset turnover—
Leverage & solvency
Liabilities / assets6.1%
Debt / equity0.00x
Current ratio19.97x
Interest coverage-129,924.00x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $925,000 | $0 | — | — |
| R&D expense | $75.01M | $60.92M | $44.39M | $47.51M | $39.16M |
| SG&A expense | $28.32M | $22.61M | $11.19M | $9.01M | $21.54M |
| Operating income | -$103.33M | -$82.61M | -$55.58M | -$56.52M | -$60.70M |
| Interest expense | $5,000 | $12,000 | $12,000 | $2,000 | — |
| Pretax income | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M |
| EBITDA | -$100.28M | -$79.41M | -$52.32M | -$53.32M | -$59.39M |
| EPS (basic) | -4.24 | -4.28 | — | -1.04 | -1.10 |
| EPS (diluted) | -4.24 | -4.28 | — | -1.04 | -1.10 |
| Weighted avg. shares (diluted) | 21.33M | 17.57M | — | 55.22M | 55.04M |
| Banking | |||||
| Net interest income | — | — | — | $1.58M | $19,000 |
| Balance sheet | |||||
| Cash & equivalents | $103.84M | $136.93M | $148.72M | $82.02M | $70.54M |
| Short-term investments | $165.17M | $175.82M | $48.95M | $0 | $0 |
| Current assets | $271.77M | $315.92M | $200.35M | $84.72M | $143.99M |
| PP&E, net | $12.79M | $15.42M | $17.17M | $20.11M | $6.45M |
| Intangibles | — | — | — | $0 | $128,000 |
| Total assets | $288.60M | $335.73M | $222.57M | $109.27M | $163.26M |
| Current liabilities | $16.41M | $15.16M | $22.97M | $6.65M | $8.64M |
| Total liabilities | $23.72M | $25.36M | $36.55M | $10.64M | $20.40M |
| Shareholders' equity | $264.89M | $310.38M | $186.02M | -$145.74M | -$91.88M |
| Shares outstanding | 15.49M | 14.85M | 12.82M | 0 | 42.46M |
| Cash flow statement | |||||
| Operating cash flow | -$77.17M | -$70.60M | -$51.42M | -$52.82M | -$47.56M |
| Capital expenditure | $1.18M | $808,000 | $321,000 | $2.23M | $3.26M |
| Free cash flow | -$78.36M | -$71.41M | -$51.74M | -$55.05M | -$50.82M |
| Investing cash flow | $14.00M | -$125.26M | $25.64M | -$2.23M | -$3.26M |
| Financing cash flow | $30.43M | $184.07M | $92.48M | $66.53M | $732,000 |
| Depreciation & amortization | $3.04M | $3.19M | $3.26M | $3.20M | $1.31M |
| Stock-based compensation | $14.18M | $8.32M | $1.42M | $1.25M | $11.56M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.